Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months

BACKGROUND: CT-P13 is a biosimilar of Remicade(®), an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD. AIMS: To assess the effectiveness and safety of CT...

Descripción completa

Detalles Bibliográficos
Autores principales: Argüelles-Arias, F., Guerra Veloz, M. F., Perea Amarillo, R., Vilches-Arenas, A., Castro Laria, L., Maldonado Pérez, B., Chaaro, D., Benítez Roldán, A., Merino, V., Ramírez, G., Caunedo Álvarez, A., Romero Gómez, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487700/
https://www.ncbi.nlm.nih.gov/pubmed/28281165
http://dx.doi.org/10.1007/s10620-017-4511-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487700/
https://www.ncbi.nlm.nih.gov/pubmed/28281165
http://dx.doi.org/10.1007/s10620-017-4511-4

Ejemplares similares